Doxazosin NDC 16571-167

NDC codes

FDA NDC Directory

Product NDC (as listed)16571-167Labeler and product segments. Claims need a package NDC.

Product NDC at billing width16571-0167Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
16571-167-01	16571016701	100 TABLET in 1 BOTTLE (16571-167-01)Marketed from May 20, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Doxazosin
Generic name (nonproprietary): doxazosin
Active ingredients: Doxazosin mesylate — 4 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Rising Pharma Holdings, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212727
Marketing start: May 20, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Antagonists (Mechanism)
Identifiers: Product ID 16571-167_c7ae6273-26c7-4116-a42a-5c82e1b59849SPL ID c7ae6273-26c7-4116-a42a-5c82e1b59849SPL set ID 508b908e-8d80-422e-8ec0-2081185f4c95RxCUI 197625, 197626, 197627, 197628UNII 86P6PQK0MUUPC 0316571168019
Pharmacologic class: alpha-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N416571016701 followed by a unit qualifier and the quantity

Package 16571-0167-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 19, 2024.

Indications (excerpt from the label)

Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should b…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212727

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212727
Product	Strength	Form · route	Labeler	Product NDC
Doxazosin	Doxazosin mesylate 1 mg/1	TabletOral	Rising Pharma Holdings, Inc.	16571-165
Doxazosin	Doxazosin mesylate 2 mg/1	TabletOral	Rising Pharma Holdings, Inc.	16571-166
Doxazosin	Doxazosin mesylate 8 mg/1	TabletOral	Rising Pharma Holdings, Inc.	16571-168